Posted inGastroenterology news Oncology
Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort
This international multicenter study demonstrates that adjuvant imatinib therapy significantly improves both recurrence-free and overall survival in patients with resected KIT exon 9-mutant GIST, providing clarity on optimal management for this biologically distinct subgroup.